WEBSITE BSE:500126 NSE: PGHL Inc. Year: 1967 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:44
Procter & Gamble Health Ltd is an India-based corporation that is frequently engaged within the manufacturing of pharmaceutical products. The Company gives healthcare merchandise. It is concerned in production and advertising over-the-counter vitamins, minerals, and supplements merchandise for a healthy life-style. The Company offers brands, consisting of Cosome, Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. The Company’s geographical segments consist of both in India and out of India. It has its production facility situa...Read More
Procter & Gamble Health Ltd is an India-based corporation that is frequently engaged within the manufacturing of pharmaceutical products. The Company gives healthcare merchandise. It is concerned in production and advertising over-the-counter vitamins, minerals, and supplements merchandise for a healthy life-style. The Company offers brands, consisting of Cosome, Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. The Company’s geographical segments consist of both in India and out of India. It has its production facility situated at Usgaon, Goa. The Company has a sterile facility with a ability of approximately 260 Mio ampoules/annum and a smooth gel production site with a capability of over 744 Mio capsules/annum. Its production site also exports to approximately 13 international locations inside P&G Personal Healthcare International. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹8530 Cr.
Stock P/E 42.4
P/B 12.2
Current Price ₹5138.7
Book Value ₹ 420.1
Face Value 10
52W High ₹6700
Dividend Yield 2.43%
52W Low ₹ 4699.7
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 |
| Other Income | 6 | 5 | 2 | 2 | 3 | 4 | 3 | 4 | 5 | 4 |
| Total Income | 311 | 315 | 255 | 286 | 317 | 314 | 314 | 343 | 330 | 378 |
| Total Expenditure | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 |
| Operating Profit | 95 | 107 | 70 | 50 | 117 | 127 | 84 | 94 | 125 | 115 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 |
| Provision for Tax | 22 | 28 | 16 | 6 | 29 | 31 | 17 | 23 | 30 | 31 |
| Profit After Tax | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 |
| Adjusted Earnings Per Share | 39.5 | 43.4 | 28 | 10.1 | 49.6 | 54.8 | 36.9 | 39.9 | 53.3 | 46.7 |
| #(Fig in Cr.) | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Mar 2024 | Jun 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 940 | 993 | 698 | 849 | 1356 | 1009 | 1114 | 1230 | 1151 | 1151 | 934 | 1349 |
| Other Income | 23 | 24 | 30 | 28 | 70 | 18 | 13 | 18 | 16 | 16 | 10 | 16 |
| Total Income | 963 | 1017 | 729 | 877 | 1426 | 1027 | 1128 | 1248 | 1167 | 1167 | 945 | 1365 |
| Total Expenditure | 856 | 877 | 628 | 705 | 1042 | 763 | 847 | 905 | 845 | 845 | 616 | 946 |
| Operating Profit | 107 | 140 | 101 | 173 | 384 | 264 | 281 | 343 | 322 | 322 | 329 | 418 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 |
| Depreciation | 23 | 25 | 19 | 21 | 29 | 30 | 27 | 28 | 27 | 27 | 17 | 22 |
| Exceptional Income / Expenses | 0 | 0 | 17 | 7 | 0 | 0 | 0 | 0 | -20 | -20 | 0 | 0 |
| Profit Before Tax | 83 | 115 | 99 | 158 | 355 | 233 | 253 | 314 | 273 | 273 | 312 | 396 |
| Provision for Tax | 30 | 36 | 38 | 56 | 101 | 56 | 61 | 85 | 72 | 72 | 77 | 101 |
| Profit After Tax | 54 | 79 | 61 | 102 | 254 | 177 | 193 | 229 | 201 | 201 | 234 | 294 |
| Adjustments | 0 | 0 | 33 | 737 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 54 | 79 | 94 | 839 | 254 | 177 | 193 | 229 | 201 | 201 | 234 | 294 |
| Adjusted Earnings Per Share | 32.3 | 47.7 | 36.8 | 61.3 | 153.1 | 106.5 | 116 | 138.2 | 121.1 | 121.1 | 141.2 | 176.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -19% | -9% | -2% | -0% |
| Operating Profit CAGR | 2% | -1% | 5% | 12% |
| PAT CAGR | 16% | 1% | 6% | 16% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -2% | 3% | -4% | 23% |
| ROE Average | 44% | 36% | 34% | 23% |
| ROCE Average | 58% | 48% | 46% | 32% |
| #(Fig in Cr.) | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Mar 2024 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 592 | 664 | 733 | 1540 | 906 | 704 | 616 | 751 | 538 | 538 | 537 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 395 | 399 | 431 | 495 | 667 | 723 | 714 | 803 | 0 | 4 | 7 |
| Total Current Liabilities | 539 | 301 | 352 | 548 | 539 | 551 | 608 | 679 | 0 | 219 | 215 |
| Total Liabilities | 1525 | 1363 | 1516 | 2583 | 2112 | 1978 | 1938 | 2233 | 0 | 761 | 759 |
| Fixed Assets | 132 | 111 | 115 | 100 | 98 | 101 | 109 | 142 | 127 | 127 | 112 |
| Other Non-Current Assets | 448 | 502 | 522 | 594 | 749 | 838 | 845 | 920 | -127 | 110 | 121 |
| Total Current Assets | 946 | 750 | 879 | 1889 | 1265 | 1039 | 984 | 1171 | 0 | 524 | 526 |
| Total Assets | 1525 | 1363 | 1516 | 2583 | 2112 | 1978 | 1938 | 2233 | 0 | 761 | 759 |
| #(Fig in Cr.) | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Mar 2024 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 5 | 9 | 26 | 10 | 1119 | 636 | 464 | 319 | 435 | 435 | 239 |
| Cash Flow from Operating Activities | 83 | 107 | 54 | -130 | 235 | 247 | 170 | 236 | 228 | 228 | 169 |
| Cash Flow from Investing Activities | -68 | -75 | -48 | 1270 | 165 | -32 | -26 | -22 | -7 | -7 | 10 |
| Cash Flow from Financing Activities | -12 | -15 | -22 | -30 | -883 | -387 | -289 | -98 | -418 | -418 | -235 |
| Net Cash Inflow / Outflow | 4 | 17 | -16 | 1109 | -483 | -172 | -145 | 116 | -197 | -197 | -56 |
| Closing Cash & Cash Equivalent | 9 | 26 | 10 | 1119 | 636 | 464 | 319 | 435 | 239 | 239 | 182 |
| # | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Mar 2024 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 32.27 | 47.67 | 36.77 | 61.29 | 153.06 | 106.51 | 115.98 | 138.23 | 121.07 | 121.07 | 141.21 |
| CEPS(Rs) | 46.37 | 62.61 | 48.29 | 74.01 | 170.8 | 124.6 | 132.29 | 155.16 | 137.58 | 137.58 | 151.27 |
| DPS(Rs) | 7.5 | 11 | 15 | 440 | 230 | 130 | 52.5 | 95 | 260 | 260 | 125 |
| Book NAV/Share(Rs) | 356.36 | 399.89 | 441.72 | 927.78 | 544.82 | 421.59 | 366.99 | 447.62 | 319.1 | 319.1 | 320.52 |
| Core EBITDA Margin(%) | 8.57 | 11.22 | 9.93 | 16.98 | 23.18 | 24.39 | 22.73 | 24.44 | 24.3 | 24.3 | 30.94 |
| EBIT Margin(%) | 8.56 | 11.18 | 13.9 | 18.61 | 26.17 | 23.21 | 21.55 | 23.71 | 21.76 | 21.76 | 30.32 |
| Pre Tax Margin(%) | 8.56 | 11.18 | 13.9 | 18.61 | 26.17 | 23.13 | 21.51 | 23.66 | 21.71 | 21.71 | 30.28 |
| PAT Margin (%) | 5.5 | 7.68 | 8.58 | 11.98 | 18.74 | 17.53 | 16.35 | 17.28 | 15.96 | 15.96 | 22.78 |
| Cash Profit Margin (%) | 7.9 | 10.09 | 11.27 | 14.47 | 20.91 | 20.5 | 18.64 | 19.39 | 18.14 | 18.14 | 24.4 |
| ROA(%) | 3.92 | 5.48 | 4.24 | 4.96 | 10.82 | 8.65 | 9.83 | 11 | 13.43 | 13.43 | 30.85 |
| ROE(%) | 9.35 | 12.61 | 8.74 | 8.95 | 20.79 | 22.04 | 29.41 | 33.94 | 31.58 | 31.58 | 44.15 |
| ROCE(%) | 14.54 | 18.35 | 14.16 | 13.9 | 29.01 | 29.08 | 38.45 | 46.07 | 42.52 | 42.52 | 58.05 |
| Receivable days | 43.3 | 41.4 | 58.92 | 40.59 | 21.73 | 28.06 | 22.2 | 27.36 | 29.14 | 29.14 | 40.92 |
| Inventory Days | 64.49 | 58.63 | 82.51 | 58.27 | 33.31 | 45.68 | 36.19 | 34.37 | 35.37 | 35.37 | 38.75 |
| Payable days | 44.71 | 61.19 | 118.32 | 116.16 | 90.99 | 177.09 | 188.51 | 206.35 | 223.07 | 223.07 | 235.41 |
| PER(x) | 24.14 | 20.93 | 35.05 | 50.32 | 26.57 | 52.52 | 36.1 | 37.97 | 38.87 | 41.71 | 36.42 |
| Price/Book(x) | 2.19 | 2.49 | 2.92 | 3.32 | 7.47 | 13.27 | 11.41 | 11.73 | 14.75 | 15.83 | 16.04 |
| Dividend Yield(%) | 0.96 | 1.1 | 1.16 | 14.27 | 5.65 | 2.32 | 1.25 | 1.81 | 5.52 | 5.15 | 2.43 |
| EV/Net Sales(x) | 1.18 | 1.39 | 2.67 | 4.57 | 4.51 | 8.74 | 5.95 | 6.73 | 6.57 | 7.07 | 8.94 |
| EV/Core EBITDA(x) | 10.35 | 9.83 | 18.42 | 22.47 | 15.91 | 33.38 | 23.59 | 24.12 | 23.53 | 25.3 | 25.39 |
| Net Sales Growth(%) | 8.3 | 5.65 | -29.66 | 21.61 | 59.7 | -25.6 | 10.48 | 10.34 | -6.37 | -6.37 | -18.86 |
| EBIT Growth(%) | 25.2 | 38.21 | -14.11 | 59.7 | 124.62 | -34.03 | 8.42 | 24.11 | -12.99 | -12.99 | 13.87 |
| PAT Growth(%) | 23.92 | 47.74 | -22.86 | 66.68 | 149.73 | -30.42 | 8.89 | 19.19 | -12.42 | -12.42 | 16.63 |
| EPS Growth(%) | 23.92 | 47.74 | -22.86 | 66.68 | 149.73 | -30.42 | 8.89 | 19.19 | -12.42 | -12.42 | 16.63 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 1.76 | 2.5 | 2.5 | 3.45 | 2.35 | 1.89 | 1.62 | 1.72 | 2.39 | 2.39 | 2.44 |
| Quick Ratio(x) | 1.45 | 1.95 | 2.05 | 3.24 | 2.1 | 1.67 | 1.43 | 1.53 | 1.9 | 1.9 | 1.94 |
| Interest Cover(x) | 0 | 0 | 0 | 0 | 0 | 292.6 | 604.26 | 409.05 | 380.61 | 380.61 | 725.7 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 51.82 | 51.82 | 51.82 | 51.82 | 51.82 | 51.82 | 51.82 | 51.82 | 51.82 | 51.82 |
| FII | 7.59 | 6.24 | 6.4 | 6.61 | 7.01 | 6.87 | 6.99 | 7.24 | 6.97 | 6.2 |
| DII | 12.67 | 13.73 | 14.56 | 14.84 | 14.71 | 14.21 | 14.16 | 13.91 | 13.84 | 13.67 |
| Public | 27.92 | 28.21 | 27.23 | 26.74 | 26.46 | 27.11 | 27.03 | 27.04 | 27.37 | 28.31 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.86 | 0.86 | 0.86 | 0.86 | 0.86 | 0.86 | 0.86 | 0.86 | 0.86 | 0.86 |
| FII | 0.13 | 0.1 | 0.11 | 0.11 | 0.12 | 0.11 | 0.12 | 0.12 | 0.12 | 0.1 |
| DII | 0.21 | 0.23 | 0.24 | 0.25 | 0.24 | 0.24 | 0.24 | 0.23 | 0.23 | 0.23 |
| Public | 0.46 | 0.47 | 0.45 | 0.44 | 0.44 | 0.45 | 0.45 | 0.45 | 0.45 | 0.47 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 | 1.66 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
